ONCOMATRYX has developed a proprietary Antibody-Drug Conjugate (ADC) platform focused on targeting Cancer-Associated Fibroblasts (CAFs) in the microenvironment of metastatic solid tumors. The company uses AI tools and Quantum Computing to assist in ADC design and candidate selection and employs proprietary payloads, dual payload strategies, and conjugation chemistry within its ADC+ platform. Its lead candidate, OMTX705, is undergoing clinical development (Phase Ib-II) with results planned for presentation at major oncology conferences in 2026, and OMTX105 is being prepared for clinical entry. ONCOMATRYX conducts collaborations with universities, hospitals and research centers in the US and Europe and is developing an ADC Fill & Finish facility in San Sebastián. The company recently raised $67 million from a mix of public and private investors to advance its clinical programs and expand its pipeline.

Total raised

$127M

Funding rounds

5

Latest round

Equity

Latest activity

Mar 2026